Analyst consensus rating
Nuvectis Pharma Analyst Rating: none
Direct answer
Nuvectis Pharma's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $35.40.
Forecast evidence checked October 17, 2026.
Get free Nuvectis Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $18.60
- Average price target
- $35.40
- High price target
- $40.00
- Low price target
- $30.00
- Low target gap
- +61.3%
- Target upside
- +90.3%
- High target gap
- +115.1%
- Target range width
- 53.8%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Nuvectis Pharma?
Nuvectis Pharma has a verified none consensus. The same dataset has an average price target of $35.40.
How far are Nuvectis Pharma's low and high targets from the recorded price?
The low target implies +61.3%, while the high target implies +115.1%.
How many analysts are included in Nuvectis Pharma's consensus?
The verified consensus includes 5 analysts.
How is Nuvectis Pharma's target upside or downside calculated?
The average target of $35.40 is divided by the recorded price of $18.60, then one is subtracted to produce +90.3%. This does not guarantee a future return.
When was Nuvectis Pharma's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.